Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.
LifeMD (Nasdaq: LFMD) closed a new senior secured revolving credit facility with Citizens Bank providing up to $50 million of total availability, consisting of $30 million committed availability plus an accordion option of up to $20 million. The facility matures on January 2, 2029. As of closing, no amount was drawn and the company stated it expects existing cash and cash flow to fund organic growth. Interest is priced on a leverage-linked grid at either Term SOFR +150–225 bps or Alternate Base Rate +50–125 bps, with unused-commitment fees of 0.225%–0.30% and no upfront fee.
LifeMD (NASDAQ: LFMD) expanded its collaboration with Novo Nordisk to offer Wegovy pill (oral semaglutide) through LifeMD’s telehealth and integrated NovoCare Pharmacy services. The U.S. FDA approved the Wegovy pill on Dec 22, 2025 as the first oral GLP-1 for chronic weight management and certain cardiovascular risk reduction. A 64-week Phase 3 trial showed 16.6% mean weight loss versus 2.7% for placebo. Eligible patients can access Wegovy pills via LifeMD starting at $149/month, with staged price increases effective Apr 15, 2026. LifeMD offers virtual visits, nationwide testing, clinical oversight, and home delivery across all 50 states.
LifeMD (Nasdaq: LFMD) announced a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share. The dividend is payable on January 15, 2026 to holders of record at the close of business on January 5, 2026. This declaration establishes the payment amount and the key record and payment dates for preferred shareholders.
LifeMD (Nasdaq: LFMD) announced on November 24, 2025 that it was recognized on the 2025 Deloitte Technology Fast 500 and on the inaugural TIME’s America’s Growth Leaders of 2026 list.
LifeMD said the honors reflect its continued revenue growth, financial stability, and expanding position in health technology driven by virtual primary care, pharmacy solutions, and growth in weight management, mental health, and hormone replacement therapy. Management highlighted investments in a differentiated enterprise platform, an affiliated compounding pharmacy, expanded insurance coverage, and strategic employer, pharma, and commercial partnerships.
LifeMD (Nasdaq: LFMD) reported Q3 2025 total revenue of $60.2M, up 13% year-over-year, and adjusted EBITDA of $5.1M, up 20%.
Telehealth revenue was $47.3M (+18%), telehealth adjusted EBITDA was $2.9M (+30%), and active telehealth subscribers were ~310,000 (+14%). The company paid off approximately $17M of debt and ended the quarter with $23.8M cash. Subsequent to quarter end, LifeMD divested its majority stake in WorkSimpli, positioning the company as a pure-play telehealth and pharmacy platform.
Guidance: Q4 2025 revenue $45M–$46M and adjusted EBITDA $3M–$4M; full-year 2025 revenue $192M–$193M (+~24%) and adjusted EBITDA $13.5M–$14.5M (+~254%).
LifeMD (Nasdaq: LFMD) announced a lower cash-pay price for GLP-1 medications Wegovy and Ozempic as part of its collaboration with Novo Nordisk. LifeMD will offer the 0.25 mg and 0.5 mg doses at $199 per month for two fills for new patients, which the company describes as the lowest cash-pay pricing nationwide.
The drugs are offered through the LifeMD Weight Management Program, which includes virtual consultations, diagnostic testing, secure messaging, and lifestyle education. LifeMD cited a strategic shift from compounded GLP-1s to direct manufacturer partnerships to align with regulatory and reimbursement trends and to scale virtual obesity and metabolic care.
LifeMD (Nasdaq: LFMD) will participate in the virtual BTIG Digital Health Forum on November 24, 2025. Management will join a virtual panel titled “Creating a Scalable Virtual Primary Care and Obesity Health Platform” at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors seeking to attend can register through their BTIG representative.
LifeMD (Nasdaq: LFMD) rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025, with the press release expected at about 4:05 p.m. ET and the call at 4:30 p.m. ET. The company expects to file a Form 12b-25 notifying the SEC of a late Form 10-Q for the period ended September 30, 2025.
LifeMD identified corrections to revenue recognition and offsetting balance sheet accounts for the twelve months ended Dec 31, 2023, twelve months ended Dec 31, 2024, and the six months ended June 30, 2025. The cumulative impact is approximately $4.6 million, or roughly 1.4% of cumulative revenue for the referenced periods. The company said the adjustments will not materially change reported revenue versus guidance and will not affect cash flow or cash position.
LifeMD (Nasdaq: LFMD) sold its majority ownership interest in WorkSimpli Software LLC in a transaction that values WorkSimpli at an approximately $65 million enterprise value. The deal closed on November 4, 2025, and LifeMD received about $22 million cash at closing, representing 91.6% of the $24.0 million base purchase price attributable to the 80% interest sold. Sellers are eligible for up to an additional $28.0 million in cash tied to growth and operational targets over the next three years.
LifeMD said it expects to use existing NOLs to offset most capital gains and will reallocate resources to expand its virtual care and pharmacy offerings, including cardiometabolic care beginning in H1 2026 and continued scaling of Rex MD and e-pharmacy products.